Fig. 4
Intact Nrf2 signaling in Atg7/Yap DKO mice; Atg7/Nrf2 DKO mice do not have evidence of increased Yap activation. a Analysis of control (Atg7F/F andAtg7F/F,YapF/F), Atg7 KO (ERT2-Alb-CRE:Atg7F/F), Atg7/Yap DKO (ERT2-Alb-CRE:Atg7F/F,YapF/F) 4 weeks post TAM injection, Atg7/Nrf2 DKO (Alb-CRE:Atg7F/F,Nrf2−/−) and Nrf2 KO (Nrf2−/−) at 9 weeks of age. b Immunoblot analysis of whole liver lysate from control, Atg7 KO, Atg7/Yap DKO, Atg7/Nrf2 DKO, and Nrf2 KO mice. Immunoblotting for Atg7, LC3, Yap, Nrf2, p62/Sqstm1, β-Tubulin. c qRT-PCR analysis of whole liver RNA for Nqo, Srxn1, Cyr61, Areg. Data normalized to β-actin expression and fold control. Data from 3 (Cyr61, Nqo, Areg) and 2 (Srxn1) independent experiments, respectively. N = 3–4 animals per group. Mean ± SD. ****P < 0.0001 as determined by one-way ANOVA and Tukey’s HSD test. ns, not significant. Data represent mean ± SD. P-values analyzed by one-way ANOVA and Tukey’s HSD. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 unless indicated otherwise
